PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November. “Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA…
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Advocacy Is Central to Patient Care, Distinguished Lecturer Says
When she saw vaping taking hold at a middle school, Kamala Nola, PharmD, MS, spoke up about concerns for the students’ risk of rheumatic disease and other health issues. At ACR Convergence 2022, Dr. Nola emphasized that every healthcare professional can act as an advocate through everyday actions.

Are You Listening? Young Patient Advocates Call for Change
PHILADELPHIA—Representatives of the Young Patients’ Autoimmune Research and Empowerment Alliance (YP AREA) led a panel titled Young Patients with Big Ideas Will Revolutionize Healthcare and Research, in which they discussed their work as advocates for adolescent and young adult (AYA) patients. YP AREA’s mission is to make autoimmune research more accessible and inclusive by involving…

Contraception, Abortion & Rheumatic Disease after Dobbs
PHILADELPHIA—As rheumatologists, we care for patients who may or may not want to become pregnant. We aren’t obstetricians or gynecologists, but several of the drugs we prescribe for active rheumatic disease can negatively affect pregnancy outcomes. It’s imperative we understand how to effectively counsel our patients with rheumatic disease on the risks and benefits of…

Understaffed, Over-Scrutinized & Feeling Powerless? ACR Advocacy Can Help
Elizabeth “Blair” Solow, MD, MSc, and Angus Worthing, MD, FACP, FACR, described the top political issues affecting rheumatology now and how ACR members can work toward practices and policies that help us better care for patients.
Considering Benzbromarone as First-Line Therapy for Gout
In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model
A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to categorize two main groups of symptoms into type 1, typically…

Advocacy Involvement ‘An Antidote to Burnout,’ Says New Government Affairs Chair Christina Downey, MD
The new chair of the ACR’s Government Affairs Committee, Dr. Downey says physicians play a vital role in helping policymakers understand how policies and laws affect patients and the practice of rheumatology.
Big Utilization Management Reform Wins in Pennsylvania, Massachusetts
Prior authorization and step therapy reform bills recently enacted in Pennsylvania and Massachusetts offer case studies into how substantive policy change can take persistence, patience and a bipartisan approach to achieve success.

Gout Research at a Glance
PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 248
- Next Page »